Marinomed Biotechnologie GmbH announced that new clinical data confirmed the effectiveness of a Carragelose-based nasal spray in the therapy of common cold. The indicates regular use of the product can significantly reduces the duration of common cold symptoms.
Sanofi announced the results of a 24-week Phase 3b clinical study showing that Lyxumia met the primary endpoint of non-inferiority in blood sugar lowering when administered either before breakfast or the main meal of the day, indicate that lixisenatide works effectively at either time of administration.
Eli Lilly and Co. announced that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. Lilly will not proceed with development of edivoxetine as an add-on treatment for depression.
Scientists have determined, at near-atomic resolution, the structure of a protein that plays a central role in the perception of pain and heat, a discovery which will offer fresh insights to drug designers searching for new and better pain treatment.
Researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.
Three major cancer research centers have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on novel immunotherapies for cancer. Juno is being launched with an initial investment of $120 million, making it one of the largest Series A biotech startups in history.
Federal regulators gave the go-ahead to Arca Biopharma to begin human clinical testing of its treatment for atrial fibrillation, the company said Wednesday.
Immunomedics said Wednesday its cancer drug IMMU-132 will receive orphan drug incentives as a treatment for small cell lung cancer. The FDA awards orphan drug status to medications that are designed to treat diseases that affect fewer than 200,000 people in the U.S.
Cell Therapeutics Inc. announced that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for Pixuvri (pixantrone).
Medivation and Astellas Pharma US announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of enzalutamide in combination with exemestane in women with advanced breast cancer that is ER+ or PgR+, and HER2 normal.
Roche and Molecular Partners AG have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
Teva and Takeda announced the signing of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate (active ingredient) formulation, for the treatment of multiple sclerosis, in Japan.
Medicines Co. has acquired a privately held drugmaker that has developed several potential treatments for serious infections in a deal that could be worth more than $400 million.
Stem cells from abdominal fat of obese women prompt breast cancer cells to proliferate by releasing the hormone leptin, according to a recently published study in Breast Cancer Research. Could this protein be a new target for breast cancer drugs? Find out…
Zyoxel has announced preliminary results from a testing by Sanofi on Zyoxel’s LiverChip platform for drug metabolism and pharmacokinetic (DMPK) studies. So for what applications was the platform especially useful in the testing? Find out...